论文部分内容阅读
目的:观察帕罗西汀联合舒肝解郁胶囊治疗脑卒中后抑郁(PSD)的临床疗效。方法:72例PSD患者,随机分为2组,各36例。2组均予以常规脑血管病治疗和康复训练。西医组予以帕罗西汀治疗。中西医组在西医组治疗基础上加用舒肝解郁胶囊治疗。2组疗程均为8周。观察并判断2组治疗前后汉密尔顿抑郁量表(HAMD)和日常生活活动量表(ADL)评分的变化,并评估其临床疗效。结果:总有效率中西医组94.44%,西医组77.78%,2组比较,差异有统计学意义(P<0.05)。治疗8周后,2组治疗后HAMD、ADL评分与治疗前比较,差异均有统计学意义(P<0.05,P<0.01),治疗后中西医组与西医组HAMD、ADL评分比较,差异均有统计学意义(P<0.05)。结论:帕罗西汀联合舒肝解郁胶囊治疗PSD的疗效明显优于单纯的帕罗西汀治疗,能明显改善其抑郁情绪,并能改善其日常生活能力,是治疗PSD较理想的药物。
Objective: To observe the clinical efficacy of paroxetine combined with Shugan Jieyu capsule in the treatment of post-stroke depression (PSD). Methods: Seventy-two PSD patients were randomly divided into two groups with 36 cases in each. Both groups were treated by conventional cerebrovascular disease and rehabilitation training. Western medicine group to paroxetine treatment. Western medicine group in the Western medicine group based on the treatment with Shugan Jieyu capsule treatment. The two groups were treated for 8 weeks. The changes of Hamilton Depression Rating Scale (HAMD) and Daily Living Activity Scale (ADL) before and after treatment were observed and evaluated. The clinical efficacy was also evaluated. Results: The total effective rate was 94.44% in the Western Medicine Group and 77.78% in the Western Medicine Group. There was significant difference between the two groups (P <0.05). After 8 weeks of treatment, HAMD and ADL scores of two groups after treatment were significantly different from those before treatment (P <0.05, P <0.01). After treatment, the differences of HAMD and ADL score between the two groups were statistically significant There was statistical significance (P <0.05). Conclusion: The therapeutic effect of paroxetine combined with Shugan Jieyu capsule is better than that of paroxetine alone. It can significantly improve the depression and improve the daily living ability of PSD. It is an ideal drug for the treatment of PSD.